Background: No data on the permanent and curative effect of bisphosphonate treatment in patients with complex regional pain syndrome type-1 (CRPS-1) are currently available. The aim of this pre-specified, open-label, observational study was to evaluate the long-term efficacy and safety of neridronate treatment.
Design: A pre-specified, open-label, extension study.
Methods: Patients treated with intramuscular (IM) placebo in the double-blind phase of the study were assigned to 100 mg intravenous (IV) neridronate treatment administered 4 times over 10 days. These patients, together with those previously treated with 400 mg IM neridronate, were followed for 1 year. Efficacy was assessed using a visual analogue scale (VAS) pain score. Changes in clinical signs and symptoms, quality of life (QoL) using the Short Form Health Survey (SF-36), and the McGill Pain Questionnaire were also assessed.
Results: Benefits on pain, clinical and functional measures were maintained and further improved over 12 months in most patients treated with neridronate administered either IM or IV. In IM-treated patients, the percentage of those defined as responders (VAS score reduction ≥ 50%) progressively increased up to day 360 to 32 of 35 patients (91.4%). Among the 27 patients referred to as responders at the end of the double-blind phase, 26 reported the same result at day 360 (96.3%). In IV-treated patients, a responder rate of 88% (22 out 25) was found at day 360 (p = 0.66 between groups). Consistent improvements were also observed for all clinical signs and functional questionnaire. No drug-related adverse events were reported during the study.
Conclusion: In patients with acute CRPS-1, the benefit in pain, clinical, and functional measures observed a few weeks after neridronate treatment administered either IM or IV is maintained and further improved over 12 months. Parenteral neridronate induces permanent disease remission preventing chronic pain and motor dysfunction.
Trial Registration: EU Clinical Trials Register (EudraCT Number): 2014-001156-28.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772942 | PMC |
| http://dx.doi.org/10.1177/1759720X221142274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benign Evolution of Complex Regional Pain Syndrome (CRPS) Type 1 in Patients Treated with Intravenous Neridronate: A Single-Center Real-Life Experience.
Pharmaceuticals (Basel)
November 2024
Medicine & Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
Objective: To investigate the long-term effects of intravenous neridronate treatment in patients with complex regional pain syndrome type 1 (CRPS) in a real-life setting.
Methods: We conducted a retrospective study on consecutive CRPS patients treated at our hospital from February 2018 to July 2023. All were treated within three months of the onset of CRPS symptoms.
Is CRPS-1 a Chronic Disabling Disease? A Long-term, Real-Life Study on Patients Treated With Neridronate.
Clin Med Insights Arthritis Musculoskelet Disord
November 2024
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Article Synopsis
- - This study focused on assessing the long-term effects of neridronate treatment on patients with Complex Regional Pain Syndrome type 1 (CRPS-1), a condition that causes severe pain and disability, particularly in the upper limbs.
- - A retrospective analysis included 49 patients who received neridronate infusions, revealing that 93.9% of them experienced a complete resolution of symptoms after an average follow-up of about 4 years, with 77.6% showing no functional limitations.
- - Key factors influencing residual disability post-treatment were found to be younger age and the delay between the onset of the disease and the start of treatment, suggesting that earlier intervention may lead to better recovery outcomes.
Efficacy and safety of neridronate in paediatric type I complex regional pain syndrome: a multicentre experience.
Clin Exp Rheumatol
September 2024
Paediatric Division, Academic Hospital of Udine, Udine, Italy.
Objectives: Evidence regarding the efficacy of neridronate in the treatment of complex regional pain syndrome type I (CRPS I) is increasing, however, very little data are available in paediatric age. Our aim was to analyse the safety and the efficacy of neridronate in a case series of children with CRPS I, according to the Budapest criteria, who did not respond to previous pharmacological and physical therapy.
Methods: We collected data of children affected by CRPS I from three paediatric rheumatology centres who received neridronate.
Paget Disease of Bone Harboring Bone Metastatic Neuroendocrine Cancer: A Case Report.
Calcif Tissue Int
May 2024
Department of Endocrinology, Clinica Polispecialistica "Casa del Sole", Formia, LT, Italy.
In this case report, we describe an uncommon case of neuroendocrine cancer of unknown origin began with cauda equina syndrome in a patient affected by Paget disease of bone (PDB). A 76-year-old man with diagnosis of PDB, without history of pain or bone deformity, developed sudden severe low back pain. Bone alkaline phosphatase was increased and MRI and whole-body scintigraphy confirmed the localization of the disease at the third vertebra of the lumbar spine.
View Article and Find Full Text PDFLong-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome.
Clin Exp Rheumatol
May 2024
Rheumatology Unit, University of Verona, Italy.
Article Synopsis
- The study investigated the effectiveness of IV neridronate for treating complex regional pain syndrome (CRPS) type I over an extended period of time, focusing on long-term outcomes and predictors of success.
- Results showed significant reductions in pain levels and improvement in symptoms like hyperalgesia, allodynia, and loss of motion, with many patients experiencing a notable decrease in pain scores within just three months.
- Factors influencing a better response to treatment included being male, having lower limb CRPS, absence of predisposing events, and observing early improvements in pain, highlighting the potential for tailored treatment approaches.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!